No significant differences were observed in demographic, clinical, or pharmacological factors across CYP27A1 rs17470271 genotypes in the DKD or non-DKD groups under dominant, recessive, and genotypic models, except for the statistically significant higher prevalence of stroke among A/A carriers in the non-DKD group under the dominant model (p = 0.038) (Supplementary Table S4). The gene discussed is CYP27A1; the disease is diabetic kidney disease.